论文部分内容阅读
目的 :观察大黄蔗虫丸对慢性肝病患者肝功能、血清肝纤维化标志物及 B超等指标的影响 ,探讨其可能存在的抗肝纤维化作用。方法 :用大黄蔗虫丸配合中药辨证治疗慢性肝病患者 36例 (治疗组 ) ,与单纯应用中药辨证治疗 32例 (对照组 )进行比较 ,观察治疗前后患者血清透明质酸 (HA)、 型前胶原 (PC )、 型胶原 ( - C)和层粘蛋白 (L N)的变化 ,观察期均在 6个月以上 ,并同时检测治疗前后的肝功能 [丙氨酸转氨酶 (AL T)、总胆红素(TBil)、白蛋白 (Alb)、球蛋白 (Glb) ]和 B超 (门静脉主干、脾静脉内径和脾厚 )等情况。结果 :治疗组患者血清肝纤维化标志物均明显下降 ,尤以 HA和 PC 下降明显 ,与治疗前比较差异有显著性意义 (P<0 .0 1) ,且治疗 6个月后肝纤维化标志物仍持续下降并接近正常组水平 (P>0 .0 5 ) ,治疗组各项指标的差值与对照组比较差异均有显著性意义 (P<0 .0 5 )。治疗后患者的肝功能指标 (AL T、TBil、Glb)均有不同程度的好转 (P<0 .0 5 ) ,多数患者的 B超指标有改善。结论 :大黄蔗虫丸可能具有减轻和抑制肝纤维化进程的作用。
Objective : To observe the effect of Dahuang Sugarcane Pills on liver function, serum fibrosis markers and B-ultrasonic indexes in patients with chronic liver disease, and to explore the possible anti-hepatic fibrosis effects. METHODS: Thirty-six patients with chronic liver disease (treatment group) were treated with Dahuang Sugarcane Pills and TCM Syndrome Differentiation. Thirty-two cases (control group) were treated with TCM syndrome differentiation. The serum HA before and after treatment was observed. Changes in collagen (PC), collagen (-C), and laminin (LN) were observed for more than 6 months, and liver function before and after treatment was also measured [ALT], total gallbladder TBil, albumin (Alb), globulin (Glb), and B-ultrasound (portal vein trunk, spleen vein inner diameter, and spleen thickness). RESULTS: Serum hepatic fibrosis markers decreased significantly in the treatment group, especially HA and PC decreased significantly compared with before treatment (P < 0.01), and liver fibrosis after 6 months of treatment. The markers continued to decline and approached the normal group level (P>0.05). The difference between the indicators in the treatment group and the control group had significant differences (P<0.05). After treatment, the liver function indexes (AL T, TBil, and Glb) of patients improved to varying degrees (P<0.05), and the B-mode ultrasound index improved in most patients. Conclusion : Dahuang Sugarcane Pill may have the effect of reducing and inhibiting the progression of hepatic fibrosis.